John B. Buse, MD, PhD

John B. Buse, MD, PhD

Office: 919-966-0134
Appts: 984-974-2950
Curriculum Vitae

UNC Health Care Profile & Star Rating

Best Docs

Verne S. Caviness Distinguished Professor
Chief, Division of Endocrinology
Director, Diabetes Center
Director, NC Translational and Clinical Sciences Institute

Specialty Areas: Prevention and treatment of type 1 diabetes, type 2 diabetes and their complications.

ChronologyMD: Duke University, 1986; PhD: Duke University, 1986; Intern and Resident: University of Chicago, 1986-1988; Endocrinology, Diabetes and Metabolism Fellowship: University of Chicago, 1988-1991; Chief Resident and Instructor: University of Chicago, 1990; Assistant Professor of Medicine: University of Chicago, 1992-1994; Associate Professor of Medicine: University of North Carolina, 1994-2006; Chief: Division of General Medicine and Clinical Epidemiology, University of North Carolina, 2001-2006; Professor of Medicine: University of North Carolina, 2006-present; Chief: Division of Endocrinology, University of North Carolina, 2006-present; Director: Diabetes Center for Excellence, University of North Carolina, 2010-present; Executive Associate Dean for Clinical Research: University of North Carolina, 2011-present; Director: NC Translational and Clinical Sciences Institute, University of North Carolina, 2015-present.

Note: Not accepting new patients at this time.

Dr. Buse’s practice combines clinical care, research and education. He has received international recognition for innovative clinical care and efforts at prevention of type 1 diabetes, type 2 diabetes and their complications. He practices patient-centered care focusing on developing treatment programs in collaboration with patients that meet their needs and expectations. He works with teams of investigators in diabetes clinical trials, comparative effectiveness research and translation of basic science research towards clinical application. Current projects focus in novel treatments including development of glucose-responsive insulin, cardiovascular safety and efficacy of diabetes drugs and developing the evidence-base for treatment guidelines of the future in diabetes care.

Selected Bibliography:

Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. El-Khatib FH, Balliro C, Hillard MA, Magyar KL, Ekhlaspour L, Sinha M, Mondesir D, Esmaeili A, Hartigan C, Thompson MJ, Malkani S, Lock JP, Harlan DM, Clinton P, Frank E, Wilson DM, DeSalvo D, Norlander L, Ly T, Buckingham BA, Diner J, Dezube M, Young LA, Goley A, Kirkman MS, Buse JB, Zheng H, Selagamsetty RR, Damiano ER, Russell SJ. Lancet. 2017 Jan 28;389(10067):369-380.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. N Engl J Med. 2016; 375(4):311-22.

Microneedles Integrated with Pancreatic Cells and Synthetic Glucose-Signal Amplifiers for Smart Insulin Delivery. Ye Y, Yu J, Wang C, Nguyen NY, Walker GM, Buse JB, Gu Z. Adv Mater. 2016; 28:3115-21.

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. Ahrén B, Hirsch IB, Pieber TR, Mathieu C, Gómez-Peralta F, Hansen TK, Philotheou A, Birch S, Christiansen E, Jensen TJ, Buse JB; ADJUNCT TWO Investigators. Diabetes Care. 2016; 39:1693-701.

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, Buse JB, Banks P, Heptulla R, Rendell M, Cefalu WT, Strumph P. Diabetes Care. 2015; 38:1181-8.